161 related articles for article (PubMed ID: 4587143)
1. Immunopotentiation with BCG. IV. Factors affecting the magnitude of an antitumor response.
Hawrylko E; Mackaness GB
J Natl Cancer Inst; 1973 Nov; 51(5):1683-8. PubMed ID: 4587143
[No Abstract] [Full Text] [Related]
2. Immunopotentiation with BCG. 3. Modulation of the response to a tumor-specific antigen.
Hawrylko E; Mackaness GB
J Natl Cancer Inst; 1973 Nov; 51(5):1677-82. PubMed ID: 4587142
[No Abstract] [Full Text] [Related]
3. Immunopotentiation with BCG: dimensions of a specific antitumor response.
Hawrylko E
J Natl Cancer Inst; 1975 May; 54(5):1189-97. PubMed ID: 805254
[TBL] [Abstract][Full Text] [Related]
4. BCG immunotherapy of rat tumors of defined immunogenicity.
Baldwin RW; Pimm MV
Natl Cancer Inst Monogr; 1973 Dec; 39():11-9. PubMed ID: 4595312
[No Abstract] [Full Text] [Related]
5. Active specific immunotherapy for acute myelogenous leukaemia.
Powles R
Johns Hopkins Med J Suppl; 1974; 3():333-40. PubMed ID: 4609353
[No Abstract] [Full Text] [Related]
6. Effect of cell-wall skeleton of Mycobacterium bovis BCG on cell-mediated cytotoxicity in tumor-bearing mice.
Taniyama T; Azuma I; Aladin AA; Yamamura Y
Gan; 1975 Dec; 66(6):705-9. PubMed ID: 817955
[TBL] [Abstract][Full Text] [Related]
7. Differential effects of two strains of BCG on transplantation immunity to SV40-induced tumors in hamsters.
Fortner GW; Hanna MG; Coggin JH
Proc Soc Exp Biol Med; 1974 Oct; 147(1):62-7. PubMed ID: 4373753
[No Abstract] [Full Text] [Related]
8. Suppression of murine tumor growth by immune reaction to the Bacillus Calmette-Guérin strain of Mycobacterium bovis.
Bartlett GL; Zbar B; Rapp HJ
J Natl Cancer Inst; 1972 Jan; 48(1):245-57. PubMed ID: 4568964
[No Abstract] [Full Text] [Related]
9. Mycobacterial cell wall components in tumor suppression and regression.
Ribi EE; Meyer TJ; Azuma I; Zbar B
Natl Cancer Inst Monogr; 1973 Dec; 39():115-9. PubMed ID: 4595311
[No Abstract] [Full Text] [Related]
10. Coupling PPD to tumour cells enhances their antigenicity in BCG-primed mice.
Lachmann PJ; Sikora K
Nature; 1978 Feb; 271(5644):463-4. PubMed ID: 342968
[No Abstract] [Full Text] [Related]
11. Histopathology of tumor regression after intralesional injection of Mycobacterium bovis. IV. Development of immunity to tumor cells and BCG.
Hanna MG; Snodgrass MJ; Zbar B; Rapp HJ
J Natl Cancer Inst; 1973 Dec; 51(6):1897-908. PubMed ID: 4358147
[No Abstract] [Full Text] [Related]
12. The use of systemic immunity adjuvants in the prophylaxis or therapy of cancer.
Mathé G; Halle-Pannenko O; Bourut C; Hiu IJ
Johns Hopkins Med J Suppl; 1974; 3():85-102. PubMed ID: 4154074
[No Abstract] [Full Text] [Related]
13. BCG in cancer immunotherapy: results obtained with various BCG preparations in a screening study for systemic adjuvants applicable to cancer immunoprophylaxis or immunotherapy.
Mathé G; Halle-Pannenko O; Bourut C
Natl Cancer Inst Monogr; 1973 Dec; 39():107-13. PubMed ID: 4150738
[No Abstract] [Full Text] [Related]
14. BCG and cancer (first of two parts).
Bast RC; Zbar B; Borsos T; Rapp HJ
N Engl J Med; 1974 Jun; 290(25):1413-20. PubMed ID: 4364286
[No Abstract] [Full Text] [Related]
15. Activated macrophages and the antitumor action of BCG.
Alexander P
Natl Cancer Inst Monogr; 1973 Dec; 39():127-33. PubMed ID: 4595313
[No Abstract] [Full Text] [Related]
16. The antileukemic effect of systemic non-specific BCG-immunostimulation vs systemic specific immunostimulation with irradiated isogeneic leukemic cells.
Olsson L; Ebbesen P; Kiger N; Florentin I; Mathé G
Eur J Cancer (1965); 1978 Apr; 14(4):355-62. PubMed ID: 348478
[No Abstract] [Full Text] [Related]
17. Effects on tumor growth in vivo by manipulation of the tumor immune response.
Sjögren HO
Johns Hopkins Med J Suppl; 1974; 3():51-60. PubMed ID: 4370816
[No Abstract] [Full Text] [Related]
18. BCG inhibition of murine leudemia: local suppression and systemic tumor immunity require different doses.
Bartlett GL; Purnell DM; Kreider JW
Science; 1976 Jan; 191(4224):299-301. PubMed ID: 1108198
[TBL] [Abstract][Full Text] [Related]
19. Immunotherapy of cancer: immunospecific rejection of tumors in recipients of neuraminidase-treated tumor cells plus BCG.
Simmons RL; Rios A
Science; 1971 Nov; 174(4009):591-3. PubMed ID: 4940021
[TBL] [Abstract][Full Text] [Related]
20. Neuraminidase-induced enhancement of tumor growth in mice.
Froese G; Berczi I; Sehon AH
J Natl Cancer Inst; 1974 Jun; 52(6):1905-8. PubMed ID: 4834417
[No Abstract] [Full Text] [Related]
[Next] [New Search]
